The two companies are working together to detect instances of the more contagious B.1.1.7 variant in the U.S. After Colorado identified the first case in the U.S. on Dec. 28, more than 60 cases have since been found across the country.
The Rochester, Minnesota-based healthcare system and San Mateo, California-based population genomics company plan to launch the study in the next few weeks.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CEO and founder Julia Cheek started EverlyWell after her own experiences trying to diagnose her own health issues highlighted problems of cost and convenience in the traditional lab testing process.
Helix is responsible for sequencing the user's DNA and passing results to PerkinElmer, which will provide data analysis and interpretative services using the company's team of medical geneticists.
Helix, based near San Francisco, touts its API-based business model as a way to stand out among the plethora of personal genomics companies.
People will be empowered through DNA if companies offer engaging and informative products built by innovative developers, powered by an advanced platform and delivered at the highest standards of quality and privacy.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Helix and Illumina Accelerator have paired up and will give entrepreneurs the chance to develop innovative, DNA-driven products geared toward consumers.
Indeed, Illumina has grown exponentially in recent years - launching spinouts such as the consumer-facing Helix and the cancer-chasing Grail, and creating an accelerator for startups in the genomics space.
Illumina has partnered with Warburg Pincus and Sutter Hill Ventures to create digital hub Helix for consumers to obtain genetic tests and complementary services from third parties.